Symbiotec Pharmalab Limited announced its financial results for the quarter ended June 30, 2026 (Q1FY27) through a regulatory filing to BSE and NSE.

Financial Performance

API Business Performance:

  • Operating Revenue: ₹215.3 crore in Q1FY27 vs ₹203.2 crore in Q1FY26 (6% YoY growth)
  • EBITDA: ₹65.8 crore in Q1FY27 vs ₹60.1 crore in Q1FY26 (9% YoY growth)
  • API Gross margins maintained upwards of 60%
  • API EBITDA margins steady at approximately 30%

Consolidated Performance:

  • Consolidated Revenues: ₹218.2 crore in Q1FY27 vs ₹203.2 crore in Q1FY26
  • Consolidated EBITDA: ₹45.2 crore in Q1FY27 vs ₹58.0 crore in Q1FY26
  • Consolidated PAT: ₹14.1 crore in Q1FY27 vs ₹29.9 crore in Q1FY26 (53% decline)
  • The decline in consolidated profitability was attributed to expenses from new businesses not yet generating revenues, including:
  • Opex: ₹23 crore
  • Depreciation: ₹12 crore

Operational Highlights

API Products:

  • Sales growth of 6% year-over-year for Q1 FY27
  • Growth expected to pick up in subsequent quarters
  • Successfully completed 4 major regulatory audits:
  • EUGMP audits at Rau and Pithampur plants in March 2026 - Approval certification received for both plants
  • USFDA audit at Rau plant in March-April 2026 - EIR received
  • USFDA audit at Pithampur plant in August 2026 - EIR awaited

Complex Injectables:

  • Licensing agreement for distribution of two DCV products in US - Term-sheet signed, agreement at advanced stage
  • Successfully filed first molecule ANDA for DCV in September 2026 - First generic filing for the DCV product in US market
  • Filing of second ANDA scheduled for early Q4 FY27

Biotech - CDMO Services:

Industrial Biotech:

  • Customers on-boarded
  • 10 years take-or-pay agreement with US-based Alternate Protein player in place
  • 10 years take-or-pay term-sheet with Europe-based Alternate Protein player in place, agreement in advanced stage

Bio-Pharmaceutical - Insulin Drug Substance (DS):

  • 5 years take-or-pay agreement in place
  • Capex on track
  • Regulatory approval filing scheduled for Q4FY27

Capex Update

  • Total gross capex estimated at approximately ₹1,666 crore by end of FY27
  • 61% of total gross capex (₹1,000 crore) invested in new revenue-generating businesses
  • Revenue for majority of new capacities already contracted
  • Revenue generation expected to commence in next 6-12 months
  • Q1FY27 gross capex invested: approximately ₹68 crore

Net Debt

  • Net Debt as on June 30, 2026: approximately ₹398 crore
  • Net Debt as on September 20, 2026 (post-IPO proceeds): approximately ₹326 crore

Management Commentary

Mr. Anil Satwani, Chairman & Managing Director, commented on the results:

  • Described the business as having "a steady growing core and two new growth engines for the future"
  • API business delivered steady revenue growth of 6% and EBITDA growth of 9%
  • Noted consistent, cash-generative growth from API business enables building new growth engines
  • In Complex Injectables, highlighted first ANDA filing from Dual Chamber Vial platform and progress toward second filing
  • In Biotech-CDMO Services, noted widening customer engagement and progress with existing conversations
  • Emphasized that innovator customers in biotech segment are "very sticky delivering a highly predictable, recurring revenue stream through take-or-pay arrangements"
  • Characterized Symbiotec as "a differentiated business"

Financial Impact

Financial impact quantified for Q1FY27 results with detailed comparative figures. Revenue generation from new businesses expected to commence in next 6-12 months.